News NICE rejects Amgen's Kyprolis in multiple myeloma NICE rejects drug despite efficacy and quality of life evidence.
News New Breakthrough status for Darzalex in earlier myeloma trea... Janssen's drug looking to gain bigger share in crowded myeloma market
News Janssen's Darzalex approved for myeloma in Europe Darzalex, a first-in-class treatment for multiple myeloma has been approved in Europe, adding to an increasingly competitive disease area.
News BMS and AbbVie’s myeloma drug Empliciti gains approval Multiple myeloma, one of the fastest-moving therapy areas, has just added another new treatment following FDA approval of Bristol-Myers Squibb's (BMS) and AbbVie's Empliciti (elotuzumab).
News FDA clears Sanofi's Type 3 Gaucher therapy Infilbray Sanofi's Infilbray has become the first drug to treat neurological symptoms of rare lysosomal storage disorder Type 3 Gaucher disease (GD3) in the US.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.